+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Incidence of tardive dyskinesia in older adult patients treated with olanzapine or conventional antipsychotics

Incidence of tardive dyskinesia in older adult patients treated with olanzapine or conventional antipsychotics

Journal of Geriatric Psychiatry and Neurology 28(1): 67-79

The risk of persistent tardive dyskinesia (TD) was compared in patients with acute psychosis or agitation aged 55 years or older who were treated with olanzapine (OLZ) or conventional antipsychotic (CNV) drug therapy. Patients without TD were randomized to treatment with OLZ (2.5-20 mg/d; n = 150) or CNV (dosed per label; n = 143). Following a 6-week drug tapering/initiation period, patients without TD were treated with OLZ or CNV for up to 1 year. The a priori defined primary outcome end point was persistent TD defined as Abnormal Involuntary Movement Scale (AIMS) scores = 2 on at least 2 items or ≥3 on at least 1 item (items 1-7) lasting at least for 1 month (Criterion A). Post hoc analyses assessed persistent TD meeting the criterion of moderate severity defined as AIMS score ≥3 on at least 1 item persisting for 1 month (Criterion B) and probable TD defined as elevated AIMS scores (Criterion A or B) not persisting for 1 month. Treatment groups were compared using Kaplan-Meier curve with log-rank exact test. On average, patients were 78 years of age; the predominant diagnosis was dementia (76.7% in the OLZ group and 82.5% in the CNV group). Approximately, 40.6% of patients in the CNV group received haloperidol. No significant difference in time to developing persistent TD was observed during treatment with OLZ or CNV (cumulative incidence: OLZ, 2.5% [95% confidence interval [95% CI]: 0.5-7.0]; CNV, 5.5% [95% CI: 2.1-11.6], P = .193). The exposure-adjusted event rates per 100 person-years were not significantly different between treatment groups: OLZ (2.7) and CNV (6.3; ratio: 0.420; 95% CI: 0.068-1.969). Post hoc analyses revealed a significantly lower risk of at least moderately severe persistent TD persisting for 1 month (P = .012) and probable TD not persisting for 1 month (Criterion A, P = .030; Criterion B, P = .048) in OLZ-treated patients. For those patients without significant extrapyramidal symptoms at baseline, significantly more patients in the CNV treatment group developed treatment-emergent parkinsonism than for patients in the OLZ treatment group (CNV: 70%, 35 of 50 patients; OLZ 44%, 25 of 57 patients; P = .011). No significant difference between the groups was observed for treatment-emergent akathisia (CNV: 6%, 7 of 117 patients; OLZ: 10%, 13 of 130 patients; P = .351). The cumulative incidence of persistent TD was low and the risk of persistent TD did not differ significantly among predominantly older adult patients having dementia with acute psychosis or agitation treated with OLZ or CNV.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 053792371

Download citation: RISBibTeXText

PMID: 25009161

DOI: 10.1177/0891988714541867

Related references

One-Year Incidence Rates of Tardive Dyskinesia in Children and Adolescents Treated with Second-Generation Antipsychotics: A Systematic Review. Yearbook of Psychiatry and Applied Mental Health 2009: 43-44, 2009

One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review. Journal of Child and Adolescent Psychopharmacology 17(5): 647-656, 2007

Tardive dyskinesia in patients treated with antipsychotics in chronic wards in Taipei. Taiwan Yi Xue Hui Za Zhi. Journal of the Formosan Medical Association 79(3): 332-337, 1980

Incidence of tardive dyskinesia with typical versus atypical antipsychotics in very high risk patients. Neurology 60(5 Suppl. 1): A126, 2003

Tardive dyskinesia and tardive dystonia with second-generation antipsychotics in non-elderly schizophrenic patients unexposed to first-generation antipsychotics: a cross-sectional and retrospective study. Journal of Clinical Psychopharmacology 35(1): 13-21, 2015

Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie 50(11): 703-714, 2005

Quetiapine, clozapine, and olanzapine in the treatment of tardive dyskinesia induced by first-generation antipsychotics: a 124-week case report. International Clinical Psychopharmacology 18(6): 357-359, 2003

Incidence of tardive dyskinesia is lower with quetiapine treatment than with typical antipsychotics in patients with schizophrenia and schizoaffective disorder. Schizophrenia Research 41(1): 206-207, 2000

Incidence of persistent tardive dyskinesia may be lower with quetiapine treatment than previously reported with typical antipsychotics in patients with psychoses. Neurology 54(7 Supp 3): A51, 2000

Tardive dyskinesia in patients treated with atypical antipsychotics: case series and brief review of etiologic and treatment considerations. Drugs in Context 3: 212259, 2014

Tardive dyskinesia, glucose and lipids with conventional and atypical antipsychotics. Schizophrenia Research 60(1): 351-352, 2003

Dose reduction of conventional antipsychotics: does it reduce tardive dyskinesia?. Tijdschrift Voor Psychiatrie 49(1): 37-41, 2007

Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. British Journal of Psychiatry 174: 23-30, 1999

Tardive dyskinesia in patients with schizophrenia treated with olanzapine - results from a 20-month, prospective, open study under naturalistic conditions. Psychiatria Polska 48(6): 1155-1165, 2015

Tardive dyskinesia rates with atypical antipsychotics in older adults. Journal of Clinical Psychiatry 65(Suppl. 9): 21-24, 2004